NOVOZYMES -B- (NZM2 BE) stock market data APIs
€53.4241
-0.38(-0.7%)
as of December 12, 2025
Try our APIs with
free plan!
NOVOZYMES -B- Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for NZM2.BE.
Prev. Close
53.4241
Open
53.0411
High
53.5175
Low
52.954
52 wk Range
49.3736-65.3076
Market Cap
19 321 M
Dividends (Yield)
0.11
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NOVOZYMES -B- data using free add-ons & libraries
Get NOVOZYMES -B- Fundamental Data
NOVOZYMES -B- Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NOVOZYMES -B- News
New
KROS or NVZMY: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS) and Novozymes A/S (NVZMY). But which of these two stocks offers valu...
Food Enzymes Market Competitive Landscape Report 2025: Players Analysis by Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue Forecast
Company Logo The global Food Enzymes market is forecasted to grow from USD 2.33 billion in 2024 to USD 3.93 billion by 2033, at a CAGR of 5.98%. Key growth drivers include increased demand in food pr...
Novozymes (CPSE:NSIS B): Assessing Valuation After Upward Sales Growth Guidance and Improved Q3 Results
Novozymes (CPSE:NSIS B) caught the market’s attention after management raised its 2025 organic sales growth guidance and reported higher sales for both the third quarter and the first nine months of...
Why Novozymes (CPSE:NSIS B) Is Up 11.4% After Raising Guidance and Reporting Strong YTD Results
On November 6, 2025, Novozymes revised its full-year 2025 earnings guidance upwards and reported financial results for the third quarter and first nine months, with sales reaching €3.16 billion and ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
